733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

von Borroto-Esoda, Katyna, Angulo, David A, Azie, Nkechi
Veröffentlicht in Open Forum Infect Dis (2020)

The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience

von Haider, Shariq, Rotstein, Coleman, Horn, David, Laverdiere, Michel, Azie, Nkechi
Veröffentlicht 2014

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis

von Sobel, Jack D., Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David
Veröffentlicht in Antimicrob Agents Chemother (2021)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

von Borroto-Esoda, Katyna, Azie, Nkechi, Ashbaugh, Alan, Cushion, Melanie, Angulo, David A
Veröffentlicht in Open Forum Infect Dis (2020)

Intravenous diltiazem and CYP3A-mediated metabolism

von Masica, Andrew L, Azie, Nkechi E, Brater, D Craig, Hall, Stephen D, Jones, David R
Veröffentlicht 2000

Safety and Pharmacokinetic Profiles of Repeated-Dose Micafungin in Children and Adolescents Treated for Invasive Candidiasis

von Benjamin, Daniel K., Deville, Jaime G., Azie, Nkechi, Kovanda, Laura, Roy, Mike, Wu, Chunzhang, Arrieta, Antonio
Veröffentlicht 2013

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, o...

von Marukutira, Tafireyi, Huprikar, Shirish, Azie, Nkechi, Quan, Shun-Ping, Meier-Kriesche, Herwig-Ulf, Horn, David L
Veröffentlicht 2014

202 Antifungal Stewardship: The Clinician's Perspective on Barriers to Implementation

von Safdar, Amar, Goff, Debra, Gallagher, Jason, Hsu, Donald, Eiland, Edward, Hanrahan, Jennifer, Smith, Purvi, Azie, Nkechi
Veröffentlicht in Open Forum Infect Dis (2014)

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis

von Gebremariam, Teclegiorgis, Wiederhold, Nathan P., Alqarihi, Abdullah, Uppuluri, Priya, Azie, Nkechi, Edwards, John E., Ibrahim, Ashraf S.
Veröffentlicht in J Antimicrob Chemother (2017)

Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents

von Hope, William W., Kaibara, Atsunori, Roy, Michael, Arrieta, Antonio, Azie, Nkechi, Kovanda, Laura L., Benjamin, Daniel K.
Veröffentlicht in Antimicrob Agents Chemother (2015)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis

von Harrington, Rachel, Lee, Edward, Yang, Hongbo, Wei, Jin, Messali, Andrew, Azie, Nkechi, Wu, Eric Q., Spalding, James
Veröffentlicht in Adv Ther (2016)

A Risk Score for Fluconazole Failure among Patients with Candidemia

von Ostrosky-Zeichner, Luis, Harrington, Rachel, Azie, Nkechi, Yang, Hongbo, Li, Nanxin, Zhao, Jing, Koo, Valerie, Wu, Eric Q.
Veröffentlicht in Antimicrob Agents Chemother (2017)

Comparing Methods of Measurement for Detecting Drug‐Induced Changes in the QT Interval: Implications for Thoroughly Conducted ECG Studies

von Azie, Nkechi E., Adams, Gregory, Darpo, Borje, Francom, Steven F., Polasek, Emery C., Wisser, Joy M., Fleishaker, Joseph C.
Veröffentlicht in Ann Noninvasive Electrocardiol (2004)

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans

von Fleishaker, Joseph C, Ryan, Kristi K, Jansat, Josep M, Carel, Barabara J, Bell, David J A, Burke, Moira T, Azie, Nkechi E
Veröffentlicht 2001

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

von Pfaller, Michael A., Andes, David R., Diekema, Daniel J., Horn, David L., Reboli, Annette C., Rotstein, Coleman, Franks, Billy, Azie, Nkechi E.
Veröffentlicht 2014

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

von Kontoyiannis, Dimitrios P., Yang, Hongbo, Song, Jinlin, Kelkar, Sneha S., Yang, Xi, Azie, Nkechi, Harrington, Rachel, Fan, Alan, Lee, Edward, Spalding, James R.
Veröffentlicht in BMC Infect Dis (2016)

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

von Andes, David, Azie, Nkechi, Yang, Hongbo, Harrington, Rachel, Kelley, Caroline, Tan, Ruo-Ding, Wu, Eric Q., Franks, Billy, Kristy, Rita, Lee, Edward, Khandelwal, Nikhil, Spalding, James
Veröffentlicht in Antimicrob Agents Chemother (2016)

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental In...

von Petraitis, Vidmantas, Petraitiene, Ruta, Katragkou, Aspasia, Maung, Bo Bo Win, Naing, Ethan, Kavaliauskas, Povilas, Barat, Stephen, Borroto-Esoda, Katyna, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Veröffentlicht in Antimicrob Agents Chemother (2020)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

von Ghannoum, Mahmoud, Arendrup, Maiken Cavling, Chaturvedi, Vishnu P., Lockhart, Shawn R., McCormick, Thomas S., Chaturvedi, Sudha, Berkow, Elizabeth L., Juneja, Deven, Tarai, Bansidhar, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Veröffentlicht in Antibiotics (Basel) (2020)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses

von Thompson, George R., Rendon, Adrian, Ribeiro dos Santos, Rodrigo, Queiroz-Telles, Flavio, Ostrosky-Zeichner, Luis, Azie, Nkechi, Maher, Rochelle, Lee, Misun, Kovanda, Laura, Engelhardt, Marc, Vazquez, Jose A., Cornely, Oliver A., Perfect, John R.
Veröffentlicht in Clin Infect Dis (2016)